Gene silence-induced downregulation of survivin inhibits bladder cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Urinary bladder cancer represents a significant global health burden, accounting for approximately 3% of all human cancers.
• Current treatment modalities for bladder cancer often yield unsatisfactory outcomes, necessitating the exploration of novel therapeutic strategies.
• Survivin, a protein involved in cell division and apoptosis, is frequently overexpressed in various cancers, including bladder cancer, making it a potential therapeutic target.

Purpose of the Study:

• To investigate the therapeutic potential of survivin gene silencing in inhibiting bladder cancer cell proliferation and inducing apoptosis.
• To elucidate the molecular mechanisms underlying survivin's role in bladder cancer progression.

Main Methods:

• Construction of lentiviral vectors carrying survivin short hairpin RNA (shRNA).
• Transduction of human bladder cancer cell lines (T24 and BJ cells) with survivin shRNA-expressing lentiviral vectors.
• Assessment of cell proliferation, cell cycle distribution (flow cytometry), and apoptosis (flow cytometry and protein analysis).

Main Results:

• Survivin shRNA significantly inhibited the proliferation of both T24 and BJ bladder cancer cells.
• Cells transfected with survivin shRNA exhibited cell cycle arrest at the G2/M phase and an increase in the sub-G1 apoptotic population.
• Deficiency in survivin led to a significant increase in the expression of pro-apoptotic proteins BAX and BAD.

Conclusions:

• Survivin gene silencing effectively suppresses bladder cancer cell proliferation and promotes apoptosis, indicating its potential as a therapeutic target.
• The observed increase in BAX and BAD protein levels suggests a mechanism by which survivin deficiency induces apoptosis in bladder cancer cells.
• Targeting survivin offers a promising strategy for the selective inhibition of bladder cancer cell growth.